Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-in-Human Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV

Next Previous
Search
Trial Profile

A Phase I, First-in-Human Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SAR 441236 (Primary) ; SAR 441236 (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 06 Mar 2024 Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 05 Mar 2024 According to ModeX Therapeutics Inc media release, data from this study presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado.
    • 05 Mar 2024 According to ModeX Therapeutics Inc media release, the study enrolled 52 participants and was conducted by the AIDS Clinical Trials Group (ACTG), a clinical trials network funded by the National Institute of Allergy and Infectious Diseases, NIH.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top